Total Funding
30
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
201328
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.
Past Role: CellCarta, Co-Founded
Michael Singer: Chief Financial Officer
Ipsen
About the Company
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown
potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.
Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.
